GlassScriptPhysician profile
Edward Legarreta
NPI 1942265988
$3,489.82
in general payments reported to CMS, 2019-2025
15 companies · $360 in 2025
The $360 reported for 2025 was more than what a typical provider received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $770 · 2020: $383 · 2021: $389 · 2022: $409 · 2023: $571 · 2024: $609 · 2025: $360.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,539.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,539.23 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $1,262.70 | 2019-2025 | Centurion, Rocklatan, Clareon |
| Biotissue Holdings INC. | $488.08 | 2019-2024 | |
| Allergan, INC. | $397.95 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $307.79 | 2019-2023 | |
| Sun Pharmaceutical Industries INC. | $267.39 | 2020-2025 | Cequa, Xelpros |
| Abbvie INC. | $255.29 | 2022-2025 | |
| Bausch & Lomb Americas INC. | $157.78 | 2022-2025 | Xiidra, Miebo, Vyzulta |
| Oyster Point Pharma, INC. | $101.98 | 2022-2024 | Tyrvaya |
| Aerie Pharmaceuticals, INC. | $83.17 | 2020-2021 | |
| Amgen INC. | $68.52 | 2025 | Tepezza |
| Genentech USA, INC. | $27.34 | 2023 | Vabysmo |
| Sandoz INC. | $22.87 | 2024 | Cimerli |
| Mallinckrodt Hospital Products INC. | $18.39 | 2023 | Acthar |
| Sight Sciences, INC. | $17.57 | 2020 | |
| Shire North American Group INC | $13.00 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Edward Legarreta listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.